![]() i-FACTOR+ Matrix is the same technology as the P15-L investigational material in the IDE,” said Jeffrey Marx, Ph.D., president and chief operating officer of Cerapedics. “In addition to the commercial launch in Canada, the latest i-FACTOR+ MATRIX generation is currently being studied in our FDA IDE study, ASPIRE, targeting lumbar fusions (TLIF), as previously announced. Although the ILS and GLS have only 34 sequence identity, the mfold program predicts. Our innovative government technology software helps government agencies unite. We conclude that the P loop is the I factor localization signal, ILS. Food and Drug Administration (FDA) premarket approval (PMA) application in 2015 only for use in single-level anterior cervical fusion procedures. KUBRA delivers a faster and more secure way to pay online with PayPal. In the United States, i-FACTOR Peptide Enhanced Bone Graft was approved via a U.S. Cerapedics initial P-15 technology product, i-FACTOR Peptide Enhanced Bone Graft, was approved in the European Union in 2008 and Australia in 2010 for use in the repair of bony voids or defects in orthopedic applications throughout the skeletal system (i.e., the spine and extremities). I-FACTOR + MATRIX utilizes a small proprietary peptide (P-15) technology developed by Cerapedics to support bone growth through cell attraction, attachment, and activation. “We are excited to announce that i-FACTOR+ Matrix is now fully available in Canada through our distributor Surgi-One and can be used in both spine and general orthopedic applications,” said Glen Kashuba, CEO of Cerapedics, “Canada will be the first market offering the i-FACTOR+ MATRIX product, which leverages the clinically proven P-15 osteogenic cell-binding peptide combined with a collagen carrier for optimized handling.” ![]() ![]() Cerapedics’ i-FACTOR + MATRIX for surgical implantation has become fully commercially available in Canada.
0 Comments
Leave a Reply. |